Corealis Pharma recently inaugurated an expansion of its facilities in Laval’s Biotech City on June 10, 2024. This expansion, funded by over $10 million, has increased the company’s premises from 33,000 to 63,000 square feet, allowing for the installation of new state-of-the-art laboratories. President of Corealis, Yves Roy, expressed immense pride in this development, emphasizing that the new facilities will enhance the company’s research and development capabilities for new drugs.
Founded in 2005 by Yves Roy, Patrick Gosselin, and Yves Mouget, Corealis quickly gained the trust of biotech companies globally and major pharmaceutical entities. It has become one of the leading Contract Research and Development Organizations (CRO/CDMOs) in the world. In 2022, Corealis entered a partnership agreement with CDPQ and Archimed, a global investment firm focused on healthcare industries, to accelerate its expansion. The company saw a 20% increase in sales in 2023, thanks to its growing clientele in various regions worldwide.
With the new expansion, Corealis Pharma aims to enhance various aspects of its operations. This includes advancements in formulation development and manufacturing of oral solid dosage forms, early-stage projects, analytical method development
